United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.
It's my pleasure to welcome you to the United Therapeutics Corporation First Quarter 2021 Earnings Call. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Mr. Michael Benkowitz, our President and Chief Operating Officer; Mr. James Edgemond, our Chief Financial Officer and Treasurer; and Dr. Leigh Peterson, our Senior Vice President of Product Development.
United Therapeutics (UTHR) delivered earnings and revenue surprises of -76.54% and 3.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?